Kasabach-Merritt syndrome natural history, complications and prognosis

Kasabach-Merritt syndrome Microchapters
Home
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Kasabach-Merritt syndrome from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Kasabach-Merritt syndrome natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Kasabach-Merritt syndrome natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Kasabach-Merritt syndrome natural history, complications and prognosis
CDC on Kasabach-Merritt syndrome natural history, complications and prognosis
Kasabach-Merritt syndrome natural history, complications and prognosis in the news
Blogs on Kasabach-Merritt syndrome natural history, complications and prognosis
Directions to Hospitals Treating Kasabach-Merritt syndrome
Risk calculators and risk factors for Kasabach-Merritt syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Complications

They are at risk of bleeding complications including intracranial hemorrhage. The thrombocytopenia and coagulopathy are managed with platelet transfusions and fresh frozen plasma, although caution is needed due to the risk of fluid overload and heart failure from multiple transfusions. The possibility of disseminated intravascular coagulation, a dangerous and difficult-to-manage condition, is concerning. Anticoagulant and antiplatelet medications can be used after careful assessment of the risks and benefits.

Prognosis

Patients with KMS can be extremely ill and may need intensive care. KMS has a mortality rate of about 30%. For patients that survive the acute disease, supportive care may be required through a gradual recovery.

Furthermore, patients may need care from a dermatologist or plastic surgeon for residual cosmetic lesions. On long-term followup, most patients have skin discoloration and/or mild disfiguration from the dormant tumor.